Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration

M.J. Reimann, J. Häggeström, J.E. Møller, J. Lykkesfeldt, T. Falk, and L.H. Olsen

Background: Cardiovascular disease has been associated with oxidative stress, which has been suggested to contribute to myocardial remodeling in human patients. Little is known about the relationship between myxomatous mitral valve disease (MMVD) and oxidative stress in dogs.

Objective: To determine whether clinical stage of MMVD is associated with changes in the plasma concentrations of certain markers of oxidative stress in clinically healthy dogs and dogs with MMVD.

Animals: Seventy five privately owned dogs: 59 cavalier King Charles Spaniels (CKCS) with different severities of MMVD and 16 dogs of different breeds with clinical signs of congestive heart failure (CHF) caused by MMVD.

Methods: Markers of oxidative stress including malondialdehyde (MDA), oxidized low-density lipoprotein (oxLDL), and vitamin E (\(\alpha\)-tocopherol and \(\gamma\)-tocopherol) were measured in plasma and their association with clinical stage of MMVD was assessed by regression analyses.

Results: Plasma oxLDL concentration was significantly lower in female dogs compared with males (\(P = .01\)). Significantly higher plasma \(\gamma\)-tocopherol concentrations were found in neutered (\(P = .003\)) dogs. Vitamin E (\(\alpha\)-tocopherol [\(P = .0004\]) and \(\gamma\)-tocopherol [\(P = .003\])] was associated with body condition score (BCS), but the association disappeared when cholesterol was included in the analyses. All markers of oxidative stress (MDA, oxLDL, and vitamin E) were positively associated with serum cholesterol concentration (\(P \leq .04\)), but none were associated with clinical stage of MMVD.

Conclusions: In conclusion, markers of oxidative stress are associated with sex, BCS, neuter status, and cholesterol. The results cannot confirm a relationship between oxidative stress and clinical stage of the disease in dogs with MMVD.

Key words: Malondialdehyde; Oxidized low-density lipoprotein; Valvular disease; Vitamin E.

Oxidative stress describes an imbalance between production of reactive oxygen species (ROS) and antioxidant defenses in the body. The ROS may cause tissue damage by oxidative modification of lipids, proteins, and DNA.

**Abbreviations:**

- ACVIM American College of Veterinary Internal Medicine
- BCS body condition score
- BW body weight
- CHF congestive heart failure
- CKCS Cavalier King Charles Spaniel
- cTnI cardiac troponin-I
- CV coefficient of variation
- DBP diastolic blood pressure
- DCM dilated cardiomyopathy
- FS fractional shortening
- IVSD\(_N\) interventricular septal thickness in diastole normalized for body weight
- IVSS\(_N\) interventricular septal thickness in systole normalized for body weight
- LA/Ao left atrial-to-aortic root ratio
- LVIDDN left ventricular end-diastolic diameter normalized for body weight
- LVIDSN left ventricular end-systolic diameter normalized for body weight
- LV left ventricular
- LVPWD\(_N\) left ventricular free wall thickness in diastole normalized for body weight
- LPWS\(_N\) left ventricular free wall thickness in systole normalized for body weight
- MBP mean blood pressure
- MDA malondialdehyde
- MMVD myxomatous mitral valve disease
- MR mitral regurgitation
- oxLDL oxidized low-density lipoprotein
- ROS reactive oxygen species
- SBP systolic blood pressure

From the Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark (Reimann, Lykkesfeldt, Olsen); Department of Clinical Sciences, Faculty of Veterinary Medicine and Animal Science, Swedish University of Agricultural Sciences, Uppsala, Sweden (Häggeström); Department of Cardiology, Odense University Hospital, Odense, Denmark (Møller); Din Veterinær, Helsingborg, Sweden (Falk).

This study was performed at the Department of Veterinary Disease Biology, University of Copenhagen, Denmark, and Din Veterinær Animal Hospital, Helsingborg, Sweden.

The study was supported financially by a PhD study grant from the Novo Nordisk—LIFE In Vivo Pharmacology Centre (LIFEPHARM) to MJR and grants from the Danish National Research Council (Project no. 271-08-0998) and Agria and the Swedish Kennel Club Research Foundation for Pets (Reg no. N2013-0017).

Results were presented as an abstract presentation at the 2016 American College of Veterinary Internal Medicine (ACVIM) Forum, Denver, Colorado.

Corresponding author: Prof. L. H. Olsen, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, 9 Ridebanevej, 1870 Frederiksberg C, Denmark; e-mail: lisbeth.hoier@sund.ku.dk

Submitted January 25, 2016; Revised November 9, 2016; Accepted November 28, 2016.

Copyright © 2017 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI: 10.1111/jvim.14647
Blood Sampling

Blood was collected from the jugular vein with a vacuum system connected to a 21-G butterfly catheter. Dogs were fasted 6–18 hours before blood sampling. To assess health status, CBC and serum biochemistry analysis was performed on all dogs. Plasma was separated by centrifugation within 30 minutes of collection and stored at cryotubes at −80°C until batched analysis was performed. Plasma vitamin E (α-tocopherol and γ-tocopherol) was analyzed in duplicate by high-performance liquid chromatography (HPLC) with electrochemical detection as previously described. Plasma MDA was determined in triplicate as its genuine MDA-thiobarbituric acid adduct by HPLC with fluorescence detection as described previously. Plasma oxLDL was assayed in triplicate with a commercially available ELISA kit according to the manufacturer’s instructions, with mouse monoclonal antibodies (mAb 4E6) against a conformational epitope at the oxidized apolipoprotein B100 of the oxLDL.

One dog with an inexplicably high concentration of plasma MDA (3.99 μmol/L) and 1 dog with an inexplicably high concentration of plasma oxLDL (35.4 U/L) were excluded from statistical analysis of MDA and oxLDL, respectively, because they were considered to be outliers based on visual inspection of the residual plots.

Plasma cardiac troponin-I (cTnI) concentration was analyzed in duplicate with an ELISA kit as described elsewhere.

Echocardiography

Echocardiographic examination was performed and evaluated by a single operator (LHO). During the offline echocardiographic analysis, the operator was blinded to the identity and clinical status of the dog. A standardized transthoracic echocardiographic examination from parasternal and apical windows was performed and digitally stored on an ultrasonographic unit with 3S and 5S ultrasound transducers and continuous electrocardiographic (ECG) monitoring.

Severity of MR was assessed from the left apical 4-chamber view by 2D color Doppler flow mapping and was classified as minimal (<20%), mild (20–50%), or moderate-severe (>50%) based on regurgitant jet area relative to left atrial area. Left atrial-to-aortic root ratio (LA/Ao) at the level of the aortic root was determined from the 2D right parasternal short-axis view. The LV dimensions and fractional shortening (FS) were obtained from M-mode short-axis images. All LV dimensions were normalized to body weight (BW).

Classification of MMVD

Clinical stage of MMVD was determined according to American College of Veterinary Internal Medicine (ACVIM) consensus statement guidelines as follows: group A (Cavalier King Charles Spaniels [CKCS] with no auscultatory heart murmur and normal echocardiogram [MR < 20%]), group B1 (CKCS with auscultatory heart murmur or MR ≥ 20% and LA/Ao ≤ 1.5), group B2 (CKCS with auscultatory heart murmur or MR ≥ 20% and LA/Ao > 1.5), and group C (dogs of various breeds with CHF). The inclusion of dog breeds other than CKCS in group C was carried out to increase the number of dogs. Classification of CHF included dogs with previous or current clinical signs of CHF (eg, cough, dyspnea, tachypnea, nocturnal restlessness, exercise intolerance), echocardiographic and radiographic changes compatible with CHF caused by MMVD, and response to treatment with diuretics.

Statistical Analysis

Data were analyzed by statistical software and the level of significance was set at P < .05.
Group associations were investigated by a nonparametric Kruskal-Wallis test because many groups did not follow a normal distribution. Exploratory differences among groups were assessed by the Wilcoxon rank sum test with Bonferroni adjustment (except for LA/Ao because this variable was used to allocate dogs into disease groups). Fisher’s exact test was performed on categorical data to investigate group differences (except for MR severity because this variable was used to allocate dogs into disease groups).

Intra-assay coefficients of variation (CV) were calculated for all markers of oxidative stress.

Univariable regression analyses were performed to evaluate associations among the markers of oxidative stress, dog characteristics (age, sex, BCS, passive smoking, neuter status), disease group, cTnI, and serum cholesterol concentration. Logarithmic transformation was performed when necessary to ensure normal distribution of data. For the purpose of statistical analysis, BCS group 3 and 4 and groups 6 and 7 were merged as only 1 dog was found with a BCS 3 and 4 dogs with a BCS 7.

Multivariable regression analysis models initially were performed including all explanatory variables with $P<.2$ in the univariable regression analysis; subsequently, analyses were repeated excluding serum cholesterol concentration as an explanatory variable. Response variable residuals were tested for homogeneity of variation based on visual inspection of residual and QQ plots and the Shapiro-Wilks test. All response variables (oxidative stress markers) were logarithmically transformed based on Box-Cox analysis. Multivariable regression analyses were performed in a backward stepwise manner based on $P$ values. Differences among groups in class variables were investigated by performing posthoc testing by Tukey-Kramer adjustment when appropriate for multiple testing.

### Results

Three dogs were excluded according to exclusion criteria. The final study population consisted of 75 dogs allocated in disease groups as follows: group A ($n=14$), group B1 ($n=27$), group B2 ($n=18$), and group C ($n=16$). Dog breeds in group C included 10 CKCS and 1 of each of the following breeds Crossbreed, Springer Spaniel, Dachshund, Bull terrier, Shetland Sheepdog, and Yorkshire Terrier. Baseline characteristics, conventional echocardiographic variables, cTnI, and concentrations of the different markers of oxidative stress of the final study population are shown in Table 1. All dogs in group C received cardiac medication as follows: diuretics ($n=15$), pimobendan ($n=12$), angiotensin converting enzyme inhibitor ($n=12$), digoxin ($n=3$), and hydralazine ($n=2$). One

### Table 1. Dog characteristics, echocardiographic variables, cardiac troponin-I, and concentrations of plasma oxidative stress markers in 75 dogs with no or different severities of myxomatous mitral valve disease.

<table>
<thead>
<tr>
<th>Disease number</th>
<th>N</th>
<th>A</th>
<th>B1</th>
<th>B2</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number</td>
<td>75</td>
<td>14</td>
<td>27</td>
<td>18</td>
<td>16</td>
</tr>
<tr>
<td>Sex (female/male)*</td>
<td>75</td>
<td>7/7</td>
<td>18/9</td>
<td>9/9</td>
<td>2/14</td>
</tr>
<tr>
<td>Age (years)</td>
<td>75</td>
<td>4.8 [4.2;5.9] 2B1,C</td>
<td>6.5 [6.0;7.8] A,C</td>
<td>7.5 [5.3;8.4] C</td>
<td>11.0 [9.6;12.9] A,B1,B2</td>
</tr>
<tr>
<td>BCS (3 + 4/5/6 + 7)</td>
<td>72</td>
<td>4/7/3</td>
<td>5/10/11</td>
<td>4/8.6</td>
<td>2/8</td>
</tr>
<tr>
<td>Passive smoking (y/n)</td>
<td>75</td>
<td>6/8</td>
<td>6/21</td>
<td>4/14</td>
<td>3/13</td>
</tr>
<tr>
<td>Neutered (y/n)</td>
<td>75</td>
<td>2/12</td>
<td>4/23</td>
<td>3/15</td>
<td>3/13</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>61</td>
<td>151 [140;164]</td>
<td>154 [143;162]</td>
<td>147 [138;155]</td>
<td>150 [143;162]</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>61</td>
<td>81 [69;87]</td>
<td>79 [74;88]</td>
<td>76 [74;79]</td>
<td>86 [79;92]</td>
</tr>
<tr>
<td>MBP (mmHg)</td>
<td>75</td>
<td>102 [100;109]</td>
<td>105 [99;112]</td>
<td>100 [98;107]</td>
<td>108 [102;116]</td>
</tr>
<tr>
<td>MR severity (min/mi/mo or se)</td>
<td>75</td>
<td>14/0.0</td>
<td>2/19.6</td>
<td>0/7.11</td>
<td>0/0/0.16</td>
</tr>
<tr>
<td>LA/Ao</td>
<td>75</td>
<td>1.3 [1.2;1.4] 2A,B2,C</td>
<td>1.4 [1.4;1.5] 2A,B2,C</td>
<td>1.6 [1.6;1.8] 2A,B2,C</td>
<td>2.2 [2.0;2.5]</td>
</tr>
<tr>
<td>LVDDaN</td>
<td>74</td>
<td>1.5 [1.4;1.5] 2A,B2,C</td>
<td>1.6 [1.4;1.6] 2A,B2,C</td>
<td>1.6 [1.5;1.6] 2A,B2,C</td>
<td>2.1 [1.9;2.3] 2A,B1,B2</td>
</tr>
<tr>
<td>LVDDsN</td>
<td>74</td>
<td>1.0 [1.0;1.1]</td>
<td>1.0 [1.0;1.1]</td>
<td>1.1 [1.0;1.2]</td>
<td>1.2 [1.1;1.4]</td>
</tr>
<tr>
<td>LVPWdN</td>
<td>74</td>
<td>0.5 [0.4;0.5]</td>
<td>0.5 [0.4;0.5]</td>
<td>0.5 [0.4;0.5]</td>
<td>0.5 [0.4;0.5]</td>
</tr>
<tr>
<td>LVPWsN</td>
<td>74</td>
<td>0.6 [0.5;0.6]</td>
<td>0.6 [0.5;0.6]</td>
<td>0.6 [0.6;0.7]</td>
<td>0.6 [0.5;0.6]</td>
</tr>
<tr>
<td>IVSDN</td>
<td>74</td>
<td>0.4 [0.3;0.4]</td>
<td>0.4 [0.4;0.5]</td>
<td>0.4 [0.4;0.5]</td>
<td>0.4 [0.4;0.4]</td>
</tr>
<tr>
<td>IVSsN</td>
<td>74</td>
<td>0.5 [0.4;0.5] 2C</td>
<td>0.5 [0.5;0.6] 2C</td>
<td>0.5 [0.4;0.6] 2C</td>
<td>0.6 [0.6;0.6] 2A,B1</td>
</tr>
<tr>
<td>Plasma cTnI (μg/L)</td>
<td>75</td>
<td>0.01 [0.01;0.02] 2C</td>
<td>0.03 [0.01;0.03] 2C</td>
<td>0.03 [0.01;0.04] 2C</td>
<td>0.04 [0.03;0.08] 2A,B1</td>
</tr>
<tr>
<td>Serum cholesterol (mmol/L)</td>
<td>75</td>
<td>5.3 [5.0;7.4]</td>
<td>6.4 [5.3;8.0]</td>
<td>6.2 [4.7;6.8] 2B2,C</td>
<td>7.4 [6.4;8.8] 2B2,C</td>
</tr>
<tr>
<td>Plasma MDA (μmol/L)</td>
<td>75</td>
<td>1.10 [0.83;1.29] 2B1,C</td>
<td>1.05 [0.84;1.30] 2B1,C</td>
<td>0.92 [0.72;1.24] 2B1,C</td>
<td>1.04 [0.86;1.12]</td>
</tr>
<tr>
<td>Plasma OxLDL (μmol/L)</td>
<td>75</td>
<td>5.65 [4.9;6.45] 2A,B2,C</td>
<td>5.73 [5.10;6.82] 2A,B2,C</td>
<td>6.27 [5.0;6.55] 2A,B2,C</td>
<td>6.07 [5.4;7.16]</td>
</tr>
<tr>
<td>Plasma neo-tocopherol (μmol/L)</td>
<td>75</td>
<td>45.36 [38.22;52.83] 2A,B2,C</td>
<td>58.48 [46.69;76.30] 2A,B2,C</td>
<td>54.92 [47.34;61.13] 2A,B2,C</td>
<td>59.63 [45.27;73.18]</td>
</tr>
<tr>
<td>Plasma γ-tocopherol (μmol/L)</td>
<td>74</td>
<td>0.98 [0.72;1.16] 2A,B2,C</td>
<td>0.94 [0.69;1.03] 2A,B2,C</td>
<td>0.81 [0.61;0.95] 2A,B2,C</td>
<td>0.94 [0.74;1.32] 2A,B2,C</td>
</tr>
</tbody>
</table>

**Table 1.** Dog characteristics, echocardiographic variables, cardiac troponin-I, and concentrations of plasma oxidative stress markers in 75 dogs with no or different severities of myxomatous mitral valve disease.

**BCS,** body condition score; **BW,** body weight; **cTnI,** cardiac troponin-I; **DBP,** diastolic blood pressure; **FS,** fractional shortening; **IVDDaN,** interventricular septal thickness in diastole normalized for BW; **IVSsN,** interventricular septal thickness in systole normalized for BW; **LA/Ao,** ratio of left atrium to aortic root; **LVDDaN,** left ventricular end-diastolic diameter normalized for BW; **LVDDsN,** left ventricular end-systolic diameter normalized for BW; **LVPWdN,** left ventricular free wall thickness in diastole normalized for BW; **LVPWsN,** left ventricular free wall thickness in systole normalized for BW; **MBP,** mean blood pressure; **MR,** mitral regurgitation by jet area method where mini=minimal, mi=mild, mo=moderate, se=severe (mini:<20%, mi:20–50%, mo or se:>50%); **SBP,** systolic blood pressure. Values reported are median and interquartiles. Within each row, superscripts A,B1,B2,C represent the group from which there is statistically significant difference.

*Sex ($P=0.008$) differed significantly among groups.
dog did not receive diuretics at the time of examination, but subsequently responded well to diuretic treatment initiated on the day of examination.

The following intra-assay CV% were obtained: MDA: 13.0%, oxLDL 9.6%, \( \alpha \)-tocopherol: 2.5%, and \( \gamma \)-tocopherol: 5.6%.

Regression Analyses

Results from the univariable regression analyses are provided in Table 2.

The final multivariable analyses resulted in the following associations: Only serum cholesterol concentration (\( \beta = 0.07 \), adjusted \( R^2 = 0.2 \), \( P = .0003 \)) was associated with plasma MDA concentration.

Plasma oxLDL was associated with sex (\( P = .01 \)) and serum cholesterol concentration (\( \beta = 0.03 \), \( P = .04 \)). The model had an adjusted \( R^2 \) of 0.1. Females had significantly lower plasma oxLDL concentration (Fig 1). When excluding serum cholesterol concentration from the analysis, sex (\( P = .01 \)) remained significant and the adjusted \( R^2 \) of this model was 0.07.

Only a positive association with serum cholesterol concentration (\( \beta = 0.15 \), adjusted \( R^2 = 0.5 \), \( P < .0001 \)) was found for plasma \( \alpha \)-tocopherol concentration. When excluding serum cholesterol from the multivariable analysis, BCS (adjusted \( R^2 = 0.2 \), \( P = .0004 \)) was significantly associated with plasma \( \alpha \)-tocopherol concentrations and dogs with BCS \( \leq 4 \) and BCS 5 had significantly lower plasma \( \alpha \)-tocopherol concentrations compared to dogs with BCS \( \geq 6 \) (Fig 2).

Regarding \( \gamma \)-tocopherol concentration, a positive association with serum cholesterol concentration (\( \beta = 0.11 \), \( P < .0001 \)) was found. Significantly increased plasma \( \gamma \)-tocopherol concentrations in neutered (\( P = .003 \)) dogs also were found (Fig 3). The adjusted \( R^2 \) of the model was 0.4. When excluding serum cholesterol concentration from the analysis, BCS (\( P = .003 \)) also was associated with plasma \( \gamma \)-tocopherol concentration (in addition to neuter status [\( P = .003 \])

Dogs with BCS 5 had significantly lower plasma \( \gamma \)-tocopherol concentrations compared to dogs with BCS \( \geq 6 \) (Fig 4). The model had an adjusted \( R^2 \) of 0.2.

Table 2. \( P \) values of the univariable analyses in 75 dogs with no or different severities of myxomatous mitral valve disease.

<table>
<thead>
<tr>
<th>Explanatory variables</th>
<th>MDA*</th>
<th>OxLDL*</th>
<th>( \alpha )-tocopherol</th>
<th>( \gamma )-tocopherol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease group</td>
<td>0.73</td>
<td>0.56</td>
<td>0.51</td>
<td>0.42</td>
</tr>
<tr>
<td>Sex</td>
<td>\textbf{0.099}</td>
<td>\textbf{0.012}</td>
<td>0.92</td>
<td>0.52</td>
</tr>
<tr>
<td>Age</td>
<td>0.88</td>
<td>0.53</td>
<td>0.20</td>
<td>0.52</td>
</tr>
<tr>
<td>BCS</td>
<td>\textbf{0.068}</td>
<td>0.31</td>
<td>\textbf{0.00045}</td>
<td>\textbf{0.0053}</td>
</tr>
<tr>
<td>Passive smoking (y/n)</td>
<td>0.85</td>
<td>0.25</td>
<td>0.28</td>
<td>0.27</td>
</tr>
<tr>
<td>Neutered (y/n)</td>
<td>0.52</td>
<td>0.28</td>
<td>0.24</td>
<td>\textbf{0.0038}</td>
</tr>
<tr>
<td>cTnI</td>
<td>0.75</td>
<td>0.90</td>
<td>\textbf{0.12}</td>
<td>0.90</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>\textbf{0.00045}</td>
<td>\textbf{0.050}</td>
<td>&lt; \textbf{0.0001}</td>
<td>&lt; \textbf{0.0001}</td>
</tr>
</tbody>
</table>

BCS, body condition score; cTnI, cardiac troponin-I; MDA = malondialdehyde; oxLDL = oxidized low-density lipoprotein; bold values represent variables with \( P < .2 \) that are included in multivariable regression analysis.

*The statistical analysis of MDA and oxLDL included 74 dogs as 1 dog was excluded (outlier).
Discussion

Our study suggests that sex differences exist for plasma oxLDL concentrations because males generally had higher plasma oxLDL concentrations. Plasma vitamin E (α-tocopherol and γ-tocopherol) concentrations were associated with BCS, but the association did not remain when including serum cholesterol concentration in the multivariable regression analysis. Additionally, significantly increased plasma γ-tocopherol concentration was found in neutered dogs. Serum cholesterol concentrations were positively associated with all of the evaluated markers of oxidative stress. An association between plasma concentrations of the selected biomarkers of oxidative stress and clinical stage of MMVD in dogs was not found.

Malondialdehyde is a secondary product formed during lipid peroxidation (ie, a reaction of oxygen with unsaturated lipids). In a previous study in dogs with MMVD, no association was found between plasma MDA and clinical stage of MMVD. This finding is in accordance with our study. In contrast, recent preliminary findings have suggested a significant relationship between plasma MDA concentrations and heart disease in a cohort of control dogs and dogs with different stages of heart disease of various causes. Plasma MDA concentrations in the studies differ however, because median MDA concentrations in the previous study were approximately 4 μM, but approximately 1 μM in the preliminary study and in our study. Breed or assay differences might account for these differences. Interestingly, the recent preliminary findings indicate higher plasma MDA concentrations in dogs with untreated CHF compared to dogs with CHF that were receiving cardiac treatment. In our study, this phenomenon could not be investigated because all dogs with CHF had received cardiac treatment. Furthermore, although we found no association between plasma MDA concentration and clinical stage of MMVD, a possible role for MDA in the volume overloaded heart may exist as a previous study found increased MDA concentrations in the cardiac tissue of dogs with volume overloaded CHF due to experimentally induced MR. These findings might indicate that changes in tissue MDA concentration in MMVD do exist but may not be reflected in plasma MDA concentrations. Similar plasma MDA concentrations as found in humans have been reported in people, but to the best of our knowledge, circulating concentrations of MDA have not been evaluated in human patients with MR.

Low-density lipoprotein is involved in cholesterol transport in the body. Oxidation of LDL has been described as part of the atherosclerotic process in humans, and several studies have identified increased concentrations of oxLDL in human patients with coronary artery disease. Furthermore, oxLDL has been suggested to mediate apoptosis in human coronary smooth muscle cells. In addition, plasma oxLDL concentration has been suggested as a useful predictor of coronary artery disease and of mortality in human patients. In our study, plasma concentrations of oxLDL were significantly higher in male dogs compared with females. To the best of our knowledge, plasma oxLDL has not been measured previously in dogs with MMVD. However, in accordance with our data, human male patients appear to have higher circulating oxLDL concentrations compared with women. Furthermore, in humans, oxLDL has been determined to be increased in patients with MR if complicated by atrial fibrillation compared with clinically healthy controls. Dogs may have lower plasma oxLDL concentrations compared with humans. This might be due to...
species differences and is in accordance with differences in lipid profiles found in humans and dogs. In our study, plasma vitamin E (α-tocopherol and γ-tocopherol) concentrations were not associated with clinical stage of MMVD. Accordingly, preliminary findings from another recent study showed no association between CHF of various causes and plasma vitamin E concentrations in dogs. Furthermore, a study in guinea pigs with experimentally induced heart failure reported no difference in myocardial vitamin E (α-tocopherol) content between sham-operated controls and sham-operated animals. Interestingly, vitamin E treatment in the guinea pigs did improve hemodynamic function (as assessed by LV function and blood pressure). The benefit of vitamin E supplementation in cardiac function also has been reported in experimentally induced MR in dogs. In the previously mentioned study, plasma vitamin E (α-tocopherol) was significantly lower in dogs with CHF (caused by MMVD or DCM), suggesting a depletion that could be caused by increased ROS scavenging. The discrepancy between vitamin E status in the present study and the previously mentioned study might be a result of the higher number of dogs included in our study, breed differences, or both. Although the reported associations differ, vitamin E concentrations in our study and previous studies on dogs with MMVD were similar. Because vitamin C is capable of regenerating vitamin E in vitro, it would have been interesting to know the vitamin C concentrations in the dogs to determine whether vitamin C had been utilized to restore vitamin E concentration in dogs with severe disease or whether neither vitamin E nor vitamin C concentrations were decreased, suggesting no alterations in antioxidant status. However, the previous study reported a significant increase in plasma vitamin C concentrations in dogs with CHF compared with healthy controls. However, because dogs in contrast to humans are capable of synthesizing vitamin C, this may be explained as a compensatory response.

A recent study in humans reported increased concentrations of biomarkers of oxidative stress and decreased circulating concentrations of antioxidants (including both α-tocopherol and γ-tocopherol) in candidates for cardiac surgery (including patients undergoing mitral valve surgery) compared with controls. Interestingly, among different etiologies of heart disease, mitral patients had the highest levels of oxidative stress and more prominent impairment of factors involved in nitric oxide generation. Compared with humans, the plasma concentrations of α-tocopherol appear to be higher, whereas the concentrations of γ-tocopherol seem to be lower, in dogs. Our study indicates a tendency toward increased vitamin E concentrations in overweight dogs. However, it is worth noticing that no severely obese dogs participated. Vitamin E is a fat-soluble vitamin stored in adipose tissue, and previous studies in humans have shown an association between vitamin E concentrations and circulating cholesterol concentrations. When serum cholesterol concentration was taken into account in our study, the association with BCS disappeared. This finding is in accordance with a study in humans reporting a positive relationship among plasma α-tocopherol, percentage fat mass, and age that disappeared when adjusting for plasma cholesterol concentration. However, results regarding the relationship between vitamin E and overweight in humans are conflicting. Another study found a positive association between body mass index and serum vitamin E (α-tocopherol) even when taking serum cholesterol concentrations into account. Vitamin E might be associated with cholesterol in dogs in a similar manner as in humans, although lipoprotein composition in dogs and humans differs. In dogs, high-density lipoprotein (suggested to protect against atherosclerosis) is the most abundant plasma lipoprotein, whereas low-density lipoprotein (suggested to contribute to atherosclerosis) dominates human plasma.

Discrepancies in markers of oxidative stress between humans and dogs may be explained by the high number of patients with ischemic heart disease included in the studies of humans whereas MMVD in dogs is considered to be of nonischemic origin and both etiology and duration of the heart disease may be of importance for these markers. However, very few studies have assessed circulating markers of oxidative stress in people with MR. Although circulating biomarkers of oxidative stress were not associated with MMVD in our study and the associations reported were relatively weak, oxidative stress may play a role in the pathogenesis of MMVD. Studies in humans and animals with experimentally induced and spontaneously occurring MR and MMVD indicate the presence of oxidative stress in the myocardium. Tissue analysis may be necessary to identify these changes as other alterations of these specific oxidative stress markers may not represent the myocardial oxidative stress levels and other circulating markers of oxidative stress may have been more informative. Previous studies in dogs have found alterations in other circulating markers of oxidative stress in dogs with MMVD compared with controls with MR.

Limitations of our study include differences in dietary regimens and supplementation which may have influenced antioxidant concentrations and markers of oxidative stress. Although the dogs were fasted for at a minimum of 6 hours before blood sampling, daily variations (partly due to variation in dietary intake) in blood concentration of vitamins may have influenced the results.

The oxLDL assay used in our study has not been formally validated in dogs (this was not possible because the assay kit is no longer commercially available) and thus actual numbers reported should be interpreted with caution. Breed differences in the dogs included differed because various breeds with CHF were included (group C) to increase the number of dogs in this group. It would have been preferable if all dogs with CHF had been CKCS.

Additionally, minor deviations from reference values in CBC and serum biochemistry results were allowed considering the high number of geriatric dogs included.
in the study. These deviations may have influenced results because they could be a sign of early or mild disease. Another limitation of our study is the different cardiac medications given to all dogs with CHF. Because individual dogs respond differently to cardiac treatment, it was not considered ethically justifiable to standardize cardiac medications. However, several types of cardiac medication have been suggested to have antioxidant properties.\textsuperscript{62–66}

Conclusions

Our results did not identify an association between clinical stage of MMVD and biomarkers of oxidative stress in dogs. However, serum cholesterol concentration was associated with all markers of oxidative stress, and oxLDL was associated with sex. Vitamin E was associated with neuter status and BCS. Circulating concentrations of MDA, oxLDL, and vitamin E may not be optimal markers for assessing the degree of oxidative stress in dogs with MMVD.

Footnotes

\begin{itemize}
\itemsuperscript{a} Vet HDO monitor (Memodiagnostic), S+B medVET GmbH, Babenhausen, Germany
\itemsuperscript{b} Merckodia AB, Uppsala, Sweden
\itemsuperscript{c} Access Systems AccuTnI Assay, Beckman Coulter Inc, Fullerton, CA
\itemsuperscript{d} EchoPAC PC. Version 112, GE Vingmed Ultrasound AS, Horten, Norway
\itemsuperscript{e} Vivid\textsuperscript{®} echocardiograph, GE-medical, Milwaukee, Wisconsin
\itemsuperscript{f} R studio, version 0.98.1091, © 2009-2014 RStudio, Inc, Boston, Massachusetts
\itemsuperscript{h} In the study by freeman et al.,\textsuperscript{11} a typographical error in the vitamin E concentration units (α-tocopherol and γ-tocopherol) should have been confirmed by the author. The reported unit μg/dL should have been μg/mL.
\end{itemize}

Acknowledgments

We thank Joan Elisabeth Frandsen and Christina Tirsdal Kjempp at Department of Veterinary Disease Biology and Dennis Jensen at Department of Veterinary Clinical and Animal Sciences, University of Copenhagen, Denmark, for their technical assistance.

Conflict of Interest Declaration: Authors declare no conflict of interest.

Off-label Antimicrobial Declaration: Authors declare no off-label use of antimicrobials.

References


